Department of Ophthalmology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
Department of Ophthalmology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands.
Ocul Immunol Inflamm. 2021 Jan 2;29(1):21-25. doi: 10.1080/09273948.2020.1712431. Epub 2020 Feb 14.
: To describe the results of tocilizumab treatment in children with refractory non-anterior uveitis.: A case series of seven children with refractory non-anterior uveitis (onset ≤16 years) with leakage on fluorescein angiogram (FA) were treated with tocilizumab intravenously every 4 weeks (eight mg/kg). Minimum follow-up was 6 months. Reported outcomes are changes in BCVA, central macular thickness (CMT) on OCT image, FA scores, dose of systemic steroids, complications and side effects.: In all patients, there was an improvement of macular edema and capillary leakage on FA. The median FA score decreased from 14 (10-18) at baseline to 8 (2-9) after 6 months of treatment (p = .018). The CMT decreased from 321 (314-384) to 295 (255-312) (p = .043). BCVA improved in five eyes and worsened in one eye due to cataract. No systemic or ocular complications were reported.: Tocilizumab is an effective therapeutic option for reducing disease activity in children with refractory non-anterior uveitis.
描述托珠单抗治疗难治性非前部葡萄膜炎儿童的结果。
对 7 例（发病年龄≤16 岁）存在荧光素眼底血管造影（FA）渗漏的难治性非前部葡萄膜炎患儿采用托珠单抗静脉输注（每 4 周 8mg/kg）进行治疗。随访时间的最低值为 6 个月。报道的结局包括视力（BCVA）、光学相干断层扫描（OCT）图像中央黄斑厚度（CMT）、FA 评分、全身皮质类固醇剂量、并发症和副作用的变化。
所有患者的黄斑水肿和 FA 毛细血管渗漏均得到改善。FA 评分中位数从基线时的 14（10-18）降至治疗 6 个月时的 8（2-9）（p =.018）。CMT 从 321（314-384）降至 295（255-312）（p =.043）。5 只眼的 BCVA 改善，1 只眼因白内障而恶化。未报道全身或眼部并发症。
托珠单抗是治疗难治性非前部葡萄膜炎儿童的有效治疗选择。
